- Home
- SYRE vs MAC Comparison
SYRE vs MAC Comparison
Compare SYRE & MAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYRE | MAC |
|---|---|---|
| Founded | 2013 | 1964 |
| Country | United States | United States |
| Employees | N/A | 2845 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 7.2B |
| IPO Year | 2015 | 1994 |
Fundamental Metrics
Financial Performance| Metric | SYRE | MAC |
|---|---|---|
| Price | $82.77 | $22.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 16 |
| Target Price | ★ $119.93 | $26.63 |
| AVG Volume (30 Days) | 1.4M | ★ 2.6M |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 3.02% |
| EPS Growth | N/A | ★ 11.36 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,013,983,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.43 |
| 52 Week Low | $21.01 | $16.03 |
| 52 Week High | $110.18 | $26.68 |
Technical Indicators
Market Signals| Indicator | SYRE | MAC |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 42.64 |
| Support Level | $82.86 | $22.06 |
| Resistance Level | $94.10 | $22.52 |
| Average True Range (ATR) | 4.63 | 0.45 |
| MACD | -0.13 | 0.04 |
| Stochastic Oscillator | 33.91 | 37.90 |
Price Performance
Historical ComparisonAbout SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and six other real estate assets. The company's total portfolio has 39.2 million square feet of gross leasable area and averaged $899 sales per square foot over the 12 months ended in March 2026.